Strut Health LegitScript and Accreditation Status: An Independent Review

What LegitScript Certification Actually Means

LegitScript certification is a voluntary third-party verification standard that confirms an online pharmacy or telehealth company meets legal dispensing requirements, employs licensed pharmacists, and dispenses only FDA-approved medications via valid prescriptions. The program is recognized by Google, Microsoft, and major payment processors, so uncertified operators can lose ad access or payment processing.

LegitScript maintains a public lookup tool at legitscript.com that lets consumers verify any domain. A search of "struthealth.com" returns no "Certified" result as of January 2025. That places Strut Health outside the verified tier used by well-known telehealth pharmacies such as Hims, Hers, and Roman, all of which carry LegitScript certification.

What the Absence of Certification Does and Does Not Mean

The absence of LegitScript certification does not, by itself, mean a platform is operating illegally. LegitScript participation is voluntary. A company could be fully compliant with state pharmacy board rules, hold valid DEA registrations, and employ board-certified physicians while simply choosing not to pay for third-party credentialing. However, the absence does remove one important external check on dispensing practices.

For consumers buying Schedule V or non-controlled prescription drugs online, the FDA's guidance on buying medicines safely online states that legitimate online pharmacies require a valid prescription from a licensed prescriber, are licensed by the state board of pharmacy in both the state where they operate and in the state where you live, and have a licensed pharmacist available to answer questions. [1]

Why Certification Matters for Compounded GLP-1 Products

Strut Health prominently markets compounded semaglutide and tirzepatide. The FDA has repeatedly clarified that compounded versions of these drugs are only permissible under specific shortage-driven circumstances. The agency's drug shortage compounding guidance specifies that 503A pharmacies may compound copies of commercially available drugs only when a shortage listing is active. [2] The FDA removed semaglutide (Ozempic, Wegovy) from its shortage list in early 2025, which triggered an enforcement timeline for compounders. Tirzepatide (Mounjaro, Zepbound) remained on shortage at the time of this review. Platforms without LegitScript oversight or equivalent credentialing are harder for regulators and consumers to audit when these rules change.

Is Strut Health a Legitimate Company?

Strut Health operates as a registered business and has been active since approximately 2018. Its physicians and nurse practitioners hold state licenses verifiable through individual state medical board lookup tools. The platform uses a standard async telemedicine intake model where a patient completes an online questionnaire and a provider reviews it before issuing a prescription.

State Licensing and Pharmacy Board Records

Telehealth platforms in the United States must comply with pharmacy practice acts in each state where they ship medications. The National Association of Boards of Pharmacy (NABP) maintains the ".pharmacy" domain program as a second voluntary credentialing layer; struthealth.com does not hold that designation. State-by-state verification requires checking each individual board, which this article cannot do exhaustively for all 50 states. Consumers in their specific state should query their state pharmacy board directly before ordering.

FDA Warning Letters and Enforcement Actions

A search of the FDA Warning Letters database shows no Warning Letter addressed directly to Strut Health as of January 2025. [3] That is a meaningful baseline. The FDA has issued Warning Letters to at least 12 compounding pharmacies and telehealth operators for unlawful distribution of compounded semaglutide since 2023, so the absence of a direct letter is notable. It does not, however, certify ongoing compliance with compounding rules that changed in early 2025.

BBB Profile and Consumer Complaints

Strut Health holds a BBB profile but is not BBB-accredited. BBB accreditation, like LegitScript, is voluntary and paid, so the lack of accreditation is not automatically disqualifying. The BBB profile as of January 2025 shows recurring consumer complaints in two categories: billing disputes (charges continuing after reported cancellation) and shipping delays for compounded products. The BBB's own guidance on online pharmacy safety flags unresolved billing disputes as a significant consumer risk indicator. [4]

How Strut Health's Compounding Pharmacy Model Works

Strut Health does not operate its own pharmacy. It acts as a telehealth prescribing platform and routes prescriptions to partner compounding pharmacies. This is a common model, but it introduces a compliance layer that patients rarely see.

503A vs. 503B Compounders

The FDA distinguishes two types of compounding pharmacies. A 503A pharmacy compounds medications for individual patients with a valid prescription and is regulated primarily by state boards. A 503B "outsourcing facility" is federally registered, subject to FDA inspection, and can produce larger batches. [5] The FDA's published list of registered 503B outsourcing facilities is publicly searchable. Strut Health's website does not clearly disclose which category its partner pharmacies fall into. That lack of disclosure makes independent verification difficult for a consumer who wants to confirm their compounded semaglutide or tirzepatide came from an FDA-inspected 503B facility.

Ingredient Sourcing and Quality

Compounded GLP-1 drugs use active pharmaceutical ingredients (APIs) sourced from suppliers. The FDA has warned that some APIs used in compounding are not the same molecular form as the branded drug. For example, semaglutide base and semaglutide sodium/acetate salts are chemically distinct from the semaglutide used in Ozempic and Wegovy. The FDA's April 2024 communication flagged this distinction explicitly and stated that the safety and efficacy of these salt forms are unknown. [6] Patients ordering from any telehealth platform, including Strut Health, should ask their prescribing provider which API form their compound uses.

Shipping and Cold-Chain Integrity

Injectable compounded peptides such as semaglutide require cold-chain shipping to maintain potency. The United States Pharmacopeia (USP) General Chapter <1> standards for sterile compounded injectables specify temperature control requirements that must be maintained during transit. Consumer complaints about shipping delays noted in Strut Health's BBB file raise a secondary question about whether cold-chain integrity is consistently maintained when packages are held at distribution centers for extended periods.

Strut Health's Core Product Lines: Clinical Context

Finasteride and Minoxidil for Hair Loss

Finasteride 1 mg daily is FDA-approved for male androgenetic alopecia. A 5-year randomized controlled trial (N=1,553) published in the Journal of the American Academy of Dermatology showed finasteride 1 mg maintained or increased hair count in 90% of men versus 75% in the placebo group at year two. [7] Topical minoxidil 5% solution received FDA approval for men in 1991. Strut Health offers both drugs, frequently as combination formulations compounded together. The individual components have strong evidence bases; the specific compounded combinations have not been evaluated in large RCTs.

Sildenafil and Tadalafil for Erectile Dysfunction

Both sildenafil and tadalafil are FDA-approved PDE5 inhibitors. The original sildenafil approval trial (N=532) showed 70% improvement in erectile function scores versus 22% placebo. [8] Tadalafil's 36-hour duration of action is supported by data from key trials published in the European Urology journal. These are off-patent drugs with well-understood safety profiles. Ordering them through any telehealth platform carries the same clinical risk profile as a traditional in-person prescription, provided the prescriber has conducted an appropriate medical history review, particularly for men taking nitrates.

Compounded Semaglutide and Tirzepatide

This is the most clinically and regulatorily complex product category Strut Health offers. The STEP-1 trial (N=1,961) showed that FDA-approved semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001). [9] The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% placebo (P<0.001). [10] These efficacy figures apply to the branded, FDA-approved formulations. Compounded versions have not been independently validated in equivalent trials.

The FDA's guidance from March 2024 states: "FDA is not able to ensure the quality, safety, and efficacy of compounded drugs in the way that it can for FDA-approved drugs." [11] That statement applies directly to compounded semaglutide and tirzepatide regardless of the platform dispensing them.

How Strut Health Compares to Credentialed Competitors

Several competing telehealth platforms carry credentials that Strut Health does not. Hims holds LegitScript certification and a NABP ".pharmacy" designation. Ro (Roman) holds LegitScript certification and publishes its state pharmacy license numbers. These credentials impose audit obligations that give consumers an independent check.

The NABP's guidance on safe online pharmacy use recommends that consumers verify NABP accreditation, confirm a valid prescription is required, and ensure the pharmacy is licensed in their state before purchasing. [12] Strut Health meets the prescription-required criterion based on its intake model but does not hold NABP accreditation.

Pricing Transparency

Strut Health's cash-pay model means pricing is visible at checkout without insurance negotiation. That transparency is a genuine advantage for patients who have been priced out of branded GLP-1 drugs, which carry list prices above $900 per month for Wegovy and $1,060 per month for Zepbound. However, price accessibility does not substitute for regulatory oversight.

Customer Support and Complaint Resolution

The pattern of billing and cancellation complaints visible on the BBB profile and on Trustpilot mirrors complaints seen against several other direct-to-consumer telehealth platforms. The American Telemedicine Association's consumer guidance on telehealth recommends reviewing cancellation policies in writing before subscribing to any telehealth service. [13] Strut Health's subscription terms should be read carefully, particularly the auto-renewal clauses, before enrollment.

Regulatory Risk Factors Specific to 2025

FDA Enforcement on Compounded Semaglutide

The FDA removed semaglutide from its drug shortage list in February 2025. Per 21 CFR 503A, 503A pharmacies cannot compound copies of commercially available drugs that are not on shortage. [14] This change means that any platform continuing to sell compounded semaglutide after that removal date is operating outside the shortage exemption. The FDA gave a 60-day wind-down period for 503A pharmacies and a 90-day period for 503B facilities. Patients who received compounded semaglutide after those deadlines should verify with their provider whether their compound remains legally dispensed.

State Attorney General Actions

Multiple state attorneys general offices investigated telehealth-compounding arrangements in 2024. No public enforcement action against Strut Health specifically has been identified in this review. The FTC's guidance on health fraud is a useful reference for consumers evaluating any online health service. [15]

What to Ask Before You Order

A patient considering Strut Health or any similar platform should ask four direct questions. First: what is the name and NABP or state license number of the dispensing pharmacy? Second: is the compounding pharmacy a 503B outsourcing facility registered with the FDA? Third: what is the molecular form of the API in any compounded injectable? Fourth: what is the cancellation policy in writing, and when does billing stop after a cancellation request?

These questions are not unique to Strut Health. They apply to every cash-pay compounding telehealth platform operating in 2025.